ZyVersa Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZVSA | FYB.DE | ZBIO | ZYME | 068270.KS | LXRX | |
|---|---|---|---|---|---|---|
| Market cap | 8.10K | — | 1.85B | 2.22B | 49.02T | 658.53M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 0.0 | 16.9 | -6.1 | 25.5 | — | -7.8 |
| Price/book | 0.0 | 0.9 | 7.3 | 27.5 | — | 3.8 |
| Dividend yield | — | — | — | — | 0.36% | — |
| 1-year change | −99.27% | −5.00% | −12.32% | +72.85% | +20.07% | +3.50% |
| Today | 0.00% | −1.68% | +0.28% | +2.69% | +7.50% | +1.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ZVSA news ›ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
Stock quotes, market indicators and the latest market news. About Inflammasome ASC Inhibitor IC 100 About ZyVersa Therapeutics, Inc. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any…
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment ...
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.financialcontent.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.